cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLC10.15829/1728-8800-2023-3671PBVGNYcardiovascular-3671Research ArticleКЛИНИКА И ФАРМАКОТЕРАПИЯCLINIC AND PHARMACOTHERAPYЭндотелийпротективный эффект питавастатинаEndothelial protective effect of pitavastatinhttps://orcid.org/0000-0003-1002-1895БернсС. А.BernsA. S.

Доктор медицинских наук, профессор, руководитель отдела изучения патогенетических аспектов старения, профессор кафедры терапии и общей врачебной практики

101990, Москва

Moscow

svberns@yandex.ruhttps://orcid.org/0000-0003-3729-616XКашталапВ. В.KashtalapV. V.

Доктор медицинских наук, доцент, зав. отделом клинической кардиологии

650002, Кемерово

Kemerovo

v_kash@mail.ruФГБУ "Национальный медицинский исследовательский центр терапии и профилактической медицины" Минздрава РоссииNational Medical Research Center for Therapy and Preventive MedicineФГБНУ "Научно-­исследовательский институт комплексных проблем сердечно-­сосудистых заболеваний"Research Institute for Complex Issues of Cardiovascular Diseases20230208202322836713671Copyright © Бернс С.А., Кашталап В.В., 20232023Бернс С.А., Кашталап В.В.Berns A.S., Kashtalap V.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/3671

В статье обсуждаются актуальные вопросы современных концепций старения, в т.ч. сосудистого старения за счет прогрессирования эндотелиальной дисфункции, формирования атеросклероза, его клиническое представление в виде хронических и острых форм сердечно-­сосудистых заболеваний. Отражены современные возможности противовозрастной терапии, направленной на замедление прогрессирования сосудистого старения и эндотелиальной дисфункции. Проведен описательный обзор литературы на основании анализа открытых литературных источников из баз данных PubMed, eLibrary, КиберЛенинка по ключевым словам: эндотелий, старение, питавастатин, противовозрастной эффект (endothelium, aging, pitavastatin, antiaging effect). На основании проведенного описательного обзора литературы показана роль питавастатина не только в качестве эффективного холестеринснижающего препарата, но и как медикаментозного агента с большим количеством доказанных плейотропных эффектов, а также оптимальным профилем безопасности и низким риском побочных эффектов и межлекарственных взаимодействий. На примере клинического случая проиллюстрированы возможности высокоинтенсивной липидснижающей терапии с применением питавастатина у коморбидного пациента.

The article discusses topical issues of modern concepts of aging, including vascular aging due to the progression of endothelial dysfunction, atherogenesis, chronic and acute cardiovascular atherosclerosis-­related diseases. Modern potential of anti-aging therapy aimed at slowing the progression of vascular aging and endothelial dysfunction are reflected. A descriptive literature review was carried out based on the analysis of sources from the PubMed, eLibrary databases for the following keywords: endothelium, aging, pitavastatin, anti-aging effect (endothelium, aging, pitavastatin, anti-aging effect). Based on a review, the role of pitavastatin is shown not only as an effective cholesterol-­lowering drug, but also as an agent with a large number of proven pleiotropic effects, as well as an optimal safety profile and a low risk of side effects and drug interactions. On the example of a case, the potential of high-intensity lipid-­lowering therapy with the use of pitavastatin in a comorbid patient are illustrated.

эндотелийстарениепитавастатинантиэйджинговый эффектendotheliumagingpitavastatinanti-aging effectReferencesLópez-­Otín C, Blasco MA, Partridge L, et al. The hallmarks of aging. Cell. 2013;153(6):1194-217. doi:10.1016/j.cell.2013.05.039.López-­Otín C, Blasco MA, Partridge L, et al. The hallmarks of aging. Cell. 2013;153(6):1194-217. doi:10.1016/j.cell.2013.05.039.Власов Т. Д., Нестерович И. И., Ши­маньски Д. А. Эндотелиальная дисфункция: от частного к общему. Возврат к "старой парадигме"? Регионарное крово­обращение и микроциркуляция. 2019;18(2):19-27. doi:10.24884/1682-6655-2019-18-2-19-27.Vlasov TD, Nesterovich II, Szymanski DA. Endothelial dy­sfunction: from private to general. A return to the "old paradigm"? Regional circulation and microcirculation. 2019;18(2):19-27. (In Russ.) doi:10.24884/1682-6655-2019-18-2-19-27.Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288:373-6. doi:10.1038/288373a0.Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288:373-6. doi:10.1038/288373a0.Садулаева И. А., Халикова Л. Ф., Медведева Е. Г. и др. Взаимосвязь маркеров эндотелиальной дисфункции с контролем артериального давления при артериальной гипертензии у пациентов с ожирением. Эффективная фармакотерапия. 2022;18(41):6-11. doi:10.33978/2307-3586-2022-18-41-6-11.Sadulaeva IA, Khalikova LF, Medvedeva EG, et al. Relationship of endothelial dysfunction markers with blood pressure control in hypertension in obese patients. Effective pharmacotherapy. 2022;18(41):6-11. (In Russ.) doi:10.33978/2307-3586-2022-18-41-6-11.Danielli JF. Capillary permeability and oedema in the perfused frog. J Physiol. 1940;98(1):109-29. doi:10.1113/jphysiol.1940.sp003837.Danielli JF. Capillary permeability and oedema in the perfused frog. J Physiol. 1940;98(1):109-29. doi:10.1113/jphysiol.1940.sp003837.Luft JH. Fine structures of capillary and endocapillary layer as revealed by ruthenium red. Fed Proc. 1966;25(6):1773-83.Luft JH. Fine structures of capillary and endocapillary layer as revealed by ruthenium red. Fed Proc. 1966;25(6):1773-83.Schött U, Solomon C, Fries D, et al. The endothelial glycocalyx and its disruption, protection and regeneration: a narrative review. Scand J Trauma Resusc Emerg Med. 2016;24:48. doi:10.1186/s13049-016-0239-y.Schött U, Solomon C, Fries D, et al. The endothelial glycocalyx and its disruption, protection and regeneration: a narrative review. Scand J Trauma Resusc Emerg Med. 2016;24:48. doi:10.1186/s13049-016-0239-y.Alphonsus CS, Rodseth RN. The endothelial glycocalyx: a review of the vascular barrier. Anaesthesia. 2014;69(7):777-84. doi:10.1111/anae.12661.Alphonsus CS, Rodseth RN. The endothelial glycocalyx: a review of the vascular barrier. Anaesthesia. 2014;69(7):777-84. doi:10.1111/anae.12661.Kolarova H, Ambruzova B, Svihalkova-­Sindlerova L, et al. Modulation of endothelial glycocalyx structure under infla­mmatory conditions. Mediators Inflamm. 2014:694312. doi:10.1155/2014/694312.Kolarova H, Ambruzova B, Svihalkova-­Sindlerova L, et al. Modulation of endothelial glycocalyx structure under infla­mmatory conditions. Mediators Inflamm. 2014:694312. doi:10.1155/2014/694312.Becker BF, Jacob M, Leipert S, et al. Degradation of the endothelial glycocalyx in clinical settings: searching for the sheddases. Br J Clin Pharmacol. 2015;80(3):389-402. doi:10.1111/bcp.12629.Becker BF, Jacob M, Leipert S, et al. Degradation of the endothelial glycocalyx in clinical settings: searching for the sheddases. Br J Clin Pharmacol. 2015;80(3):389-402. doi:10.1111/bcp.12629.Yen W, Cai B, Yang J, et al. Endothelial surface glycocalyx can regulate flow-induced nitric oxide production in microvessels in vivo. PLoS One. 2015;10(1):e0117133. doi:10.1371/journal.pone.0117133.Yen W, Cai B, Yang J, et al. Endothelial surface glycocalyx can regulate flow-induced nitric oxide production in microvessels in vivo. PLoS One. 2015;10(1):e0117133. doi:10.1371/journal.pone.0117133.Reitsma S, Slaaf DW, Vink H, et al. The endothelial glycocalyx: composition, functions, and visualization. Pflugers Arch. 2007;454(3):345-59. doi:10.1007/s00424-007-0212-8.Reitsma S, Slaaf DW, Vink H, et al. The endothelial glycocalyx: composition, functions, and visualization. Pflugers Arch. 2007;454(3):345-59. doi:10.1007/s00424-007-0212-8.Bleakley C, Hamilton PK, Pumb R, et al. Endothelial Function in Hypertension: Victim or Culprit? The Journal of Clinical Hypertension. 2015;17(8):651-4. doi:10.1111/jch.12546.Bleakley C, Hamilton PK, Pumb R, et al. Endothelial Function in Hypertension: Victim or Culprit? The Journal of Clinical Hypertension. 2015;17(8):651-4. doi:10.1111/jch.12546.Bernatova I. Endothelial Dysfunction in Experimental Models of Arterial Hypertension: Cause or Consequence? BioMed Research International. 2014;(2014):1-14. doi:10.1155/2014/598271.Bernatova I. Endothelial Dysfunction in Experimental Models of Arterial Hypertension: Cause or Consequence? BioMed Research International. 2014;(2014):1-14. doi:10.1155/2014/598271.Liu X, Ma D, Zheng S, et al. The roles of nitric oxide and hydrogen sulfide in the anti-atherosclerotic effect of atorvastatin. J Cardiovasc Med. 2015;16(1):22-8. doi:10.2459/JCM.0000000000000012.Liu X, Ma D, Zheng S, et al. The roles of nitric oxide and hydrogen sulfide in the anti-atherosclerotic effect of atorvastatin. J Cardiovasc Med. 2015;16(1):22-8. doi:10.2459/JCM.0000000000000012.Tatsumi K, Mackman N. Tissue Factor and Atherothrombosis. J Atheroscler Thromb. 2015;22(6):543-9. doi:10.5551/jat.30940.Tatsumi K, Mackman N. Tissue Factor and Atherothrombosis. J Atheroscler Thromb. 2015;22(6):543-9. doi:10.5551/jat.30940.Torimoto K, Okada Y, Tanaka Y. Type 2 Diabetes and Vascular Endothelial Dysfunction. J UOEH. 2018;40(1):65-75. doi:10.7888/juoeh.40.65.Torimoto K, Okada Y, Tanaka Y. Type 2 Diabetes and Vascular Endothelial Dysfunction. J UOEH. 2018;40(1):65-75. doi:10.7888/juoeh.40.65.Kaur R, Kaur M, Singh J. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies. Cardiovasc Diabetol. 2018;17(1):121. doi:10.1186/s12933-018-0763-3.Kaur R, Kaur M, Singh J. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies. Cardiovasc Diabetol. 2018;17(1):121. doi:10.1186/s12933-018-0763-3.Zhou Y, Wang Y, Wang G, et al. Association Between Statin Use and Progression of Arterial Stiffness Among Adults With High Atherosclerotic Risk. JAMA Netw Open. 2022;5(6):e2218323. doi:10.1001/jamanetworkopen.2022.18323.Zhou Y, Wang Y, Wang G, et al. Association Between Statin Use and Progression of Arterial Stiffness Among Adults With High Atherosclerotic Risk. JAMA Netw Open. 2022;5(6):e2218323. doi:10.1001/jamanetworkopen.2022.18323.Катапано А., Кухарчук В. В., Сергиенко И. В. и др. Питавастатин — современный статин для коррекции дислипидемии и риска сердечно-­сосудистых осложнений. Резолюция экспертного совета. Атеросклероз и дислипидемии. 2017;2:104-7. EDN: YTZWYZ.Katapano A, Kukharchuk VV, Sergienko IV, et al. Pitavastatin is a modern statin for the correction of dyslipidemia and the risk of cardiovascular complications. Expert Council Resolution. Ateroskleroz i dislipidemii. 2017;2:104-6. (In Russ.) EDN: YTZWYZ.Weng TC, Yang YH, Lin SJ, et al. A systematic review and metaanalysis on the therapeutic equivalence of statins. J Clin Pharm Ther. 2010;35(2):139-51. doi:10.1111/j.1365-2710.2009.01085.x.Weng TC, Yang YH, Lin SJ, et al. A systematic review and metaanalysis on the therapeutic equivalence of statins. J Clin Pharm Ther. 2010;35(2):139-51. doi:10.1111/j.1365-2710.2009.01085.x.Warita S, Kawasaki M, Tanaka R, et al. Effects of pitavastatin on cardiac structure and function and on prevention of atrial fibrillation in elderly hypertensive patients: a prospective study of 2-years follow-up. Circ J. 2012;76(12):2755-62. doi:10.1253/circj.cj-12-0722.Warita S, Kawasaki M, Tanaka R, et al. Effects of pitavastatin on cardiac structure and function and on prevention of atrial fibrillation in elderly hypertensive patients: a prospective study of 2-years follow-up. Circ J. 2012;76(12):2755-62. doi:10.1253/circj.cj-12-0722.Ford I, Murray H, McCowan C, et al. Long-­Term Safety and Efficacy of Lowering LDL Cholesterol With Statin Therapy: 20-Year Follow-­Up of West of Scotland Coronary Prevention Study. Circulation. 2016;133:1073-80. doi:10.1161/CIRCU­LATIONAHA.115.019014.Ford I, Murray H, McCowan C, et al. Long-­Term Safety and Efficacy of Lowering LDL Cholesterol With Statin Therapy: 20-Year Follow-­Up of West of Scotland Coronary Prevention Study. Circulation. 2016;133:1073-80. doi:10.1161/CIRCU­LATIONAHA.115.019014.Thakker D, Nair S, Pagada A, et al. Statin use and the risk of developing diabetes: a network meta-analysis. Pharmacoepidemiol Drug Saf. 2016;25(10):1131-49. doi:10.1002/pds.4020.Thakker D, Nair S, Pagada A, et al. Statin use and the risk of developing diabetes: a network meta-analysis. Pharmacoepidemiol Drug Saf. 2016;25(10):1131-49. doi:10.1002/pds.4020.Kawai Y, Sato-­Ishida R, Motoyama A, et al. Place of pitavastatin in the statin armamentarium: promising evidence for a role in diabetes mellitus. Drug Des Devel Ther. 2011;5:283-97. doi:10.2147/DDDT.S13492.Kawai Y, Sato-­Ishida R, Motoyama A, et al. Place of pitavastatin in the statin armamentarium: promising evidence for a role in diabetes mellitus. Drug Des Devel Ther. 2011;5:283-97. doi:10.2147/DDDT.S13492.Teramoto T. Pitavastatin: clinical effects from the LIVES Study. Atheroscler. 2011;12:285-8. doi:10.1016/S1567-5688(11)70888-1.Teramoto T. Pitavastatin: clinical effects from the LIVES Study. Atheroscler. 2011;12:285-8. doi:10.1016/S1567-5688(11)70888-1.Yamazaki T, Kishimoto J, Ito C, et al. Japan Prevention Trial of Diabetes by Pitavastatin in Patients with Impaired Glucose Tolerance (the J-PREDICT study): rationale, study design, and clinical characteristics of 1269 patients. Diabetol Int. 2011;2:134-40. doi:10.1007/s13340-011-0032-0.Yamazaki T, Kishimoto J, Ito C, et al. Japan Prevention Trial of Diabetes by Pitavastatin in Patients with Impaired Glucose Tolerance (the J-PREDICT study): rationale, study design, and clinical characteristics of 1269 patients. Diabetol Int. 2011;2:134-40. doi:10.1007/s13340-011-0032-0.Sasaki J, Ikeda Y, Kuribayashi T, et al. A 52-week, randomized, open-label, parallel-­group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Clin Ther. 2008;30(6):1089-101. doi:10.1016/j.clinthera.2008.05.017.Sasaki J, Ikeda Y, Kuribayashi T, et al. A 52-week, randomized, open-label, parallel-­group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Clin Ther. 2008;30(6):1089-101. doi:10.1016/j.clinthera.2008.05.017.Arai H, Hiro T, Kimura T, et al. More intensive lipid lowering is associated with regression of coronary atherosclerosis in diabetic patients with acute coronary syndrome — sub-analysis of JAPAN-ACS study. J Atheroscler Thromb. 2010;17(10):1096-107. doi:10.5551/jat.5660.Arai H, Hiro T, Kimura T, et al. More intensive lipid lowering is associated with regression of coronary atherosclerosis in diabetic patients with acute coronary syndrome — sub-analysis of JAPAN-ACS study. J Atheroscler Thromb. 2010;17(10):1096-107. doi:10.5551/jat.5660.Nomura S, Shouzu A, Omoto S, et al. Correlation between adiponectin and reduction of cell adhesion molecules after pitavastatin treatment in hyperlipidemic patients with type 2 diabetes mellitus. Thromb Res. 2008;122(1):39-45. doi:10.1016/j.thromres.2007.08.013.Nomura S, Shouzu A, Omoto S, et al. Correlation between adiponectin and reduction of cell adhesion molecules after pitavastatin treatment in hyperlipidemic patients with type 2 diabetes mellitus. Thromb Res. 2008;122(1):39-45. doi:10.1016/j.thromres.2007.08.013.Sakabe K, Fukuda N, Fukuda Y, et al. Comparisons of short-and intermediate-term effects of pitavastatin versus atorvastatin on lipid profiles, fibrinolytic parameter, and endothelial function. Int J Cardiol. 2008;125(1):136-8. doi:10.1016/j.ijcard.2007.01.040.Sakabe K, Fukuda N, Fukuda Y, et al. Comparisons of short-and intermediate-term effects of pitavastatin versus atorvastatin on lipid profiles, fibrinolytic parameter, and endothelial function. Int J Cardiol. 2008;125(1):136-8. doi:10.1016/j.ijcard.2007.01.040.Markle RA, Han J, Summers BD, et al. Pitavastatin alters the expression of thrombotic and fibrinolytic proteins in human vascular cells. J Cell Biochem. 2003;90:23-32. doi:10.1002/jcb.10602.Markle RA, Han J, Summers BD, et al. Pitavastatin alters the expression of thrombotic and fibrinolytic proteins in human vascular cells. J Cell Biochem. 2003;90:23-32. doi:10.1002/jcb.10602.Wang J, Tokoro T, Matsui K, et al. Pitavastatin at low dose activates endothelial nitric oxide synthase through PI3K-AKT pathway in endothelial cells. Life Sci. 2005;76(19):2257-68. doi:10.1016/j.lfs.2004.12.003.Wang J, Tokoro T, Matsui K, et al. Pitavastatin at low dose activates endothelial nitric oxide synthase through PI3K-AKT pathway in endothelial cells. Life Sci. 2005;76(19):2257-68. doi:10.1016/j.lfs.2004.12.003.Ohbayashi H, Miyazawa C, Miyamoto K. Pitavastatin improves plasma pentraxin 3 and arterial stiffness in atherosclerotic patients with hypercholesterolemia. J Atheroscler Thromb. 2009;16(4):490-500. doi:10.5551/jat.no613.Ohbayashi H, Miyazawa C, Miyamoto K. Pitavastatin improves plasma pentraxin 3 and arterial stiffness in atherosclerotic patients with hypercholesterolemia. J Atheroscler Thromb. 2009;16(4):490-500. doi:10.5551/jat.no613.Седых Д. Ю., Хрячкова О. Н., Каш­талап В. В. Лечение коморбидных пациентов с дислипидемией в реальной клинической практике: возможности питавастатина. РМЖ. Медицинское обозрение. 2021;5(4):218-24. doi:10.32364/2587-6821-2021-5-4-218-224.Sedykh DYu, Khryachkova ON, Kashtalap VV, et al. Treatment for dyslipidemia in comorbid patients in real clinical practice: potentialities of pitavastatin. Russian Medical Inquiry. 2021;5(4):218-24. (In Russ.) doi:10.32364/2587-6821-2021-5-4-218-224.Srichatrapimuk S, Wongsa A, Sungkanuparph S, et al. Effects of pitavastatin on atherosclerotic-­associated inflammatory biomarkers in people living with HIV with dyslipidemia and receiving ritonavir-­boosted atazanavir: a randomized, double-­blind, crossover study. AIDS Res Ther. 2023;20(1):13. doi:10.1186/s12981-023-00506-2.Srichatrapimuk S, Wongsa A, Sungkanuparph S, et al. Effects of pitavastatin on atherosclerotic-­associated inflammatory biomarkers in people living with HIV with dyslipidemia and receiving ritonavir-­boosted atazanavir: a randomized, double-­blind, crossover study. AIDS Res Ther. 2023;20(1):13. doi:10.1186/s12981-023-00506-2.Троицкая Е. А., Вельмакин С. В., Кобалава Ж. Д. Концепция сосудистого возраста: новый инструмент оценки сердечно-­сосудистого риска. Артериальная гипертензия. 2017;23(2):160-71. doi:10.18705/1607-419Х-2017-23-2-160-171.Troitskaya EA, Velmakin SV, Kobalava ZD. Concept of vascular age: new tool in cardiovascular risk assessment. Arterial Hypertension. 2017;23(2):160-71. (In Russ.) doi:10.18705/1607-419Х-2017-23-2-160-171.

The authors declare that there are no conflicts of interest present.